WISER-P: Real-world testing of software for measuring bone disease on whole-body MRI in patients with prostate cancer

Disease Site: Prostate cancer

Treatment Modality: Imaging

Status: In set-up

Trial Details

WISER-P is a prospective, randomised, multi-centre, controlled trial comparing the clinical performance of whole-body MRI (WBMRI), used with novel software, and conventional imaging (CT & bone scan), to assess treatment response of bone disease in patients with bone predominant metastatic castration resistant prostate cancer (mCRPC).

126 patients will be recruited from 8-10 UK sites over an 18 month period. All patients will undergo imaging, according to their randomised group, prior to commencement of systemic treatment and again at 8-9 weeks from start of treatment and patients will be followed up for a minimum 12 months from start of treatment.

Further Information

Chief Investigator: Professor Dow-Mu Koh. The Royal Marsden NHS Trust.

ICR-CTSU Scientific Lead: Dr Nuria Porta

Trial Management Contact: [email protected]

ISRCTN: 54072577

Sponsor: The Institute of Cancer Research

Funding: National Institute for Health Research i4i (Invention for Innovation) Challenge Award

View WISER-P on the National Institute for Health Research website: NIHR - Be Part Of Research.

A lay summary in plain English will soon be available from Cancer Research UK.

Publications and Presentations